Phaseline

Targets › NPR1

NPR1 (Atrial natriuretic peptide receptor 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2030.

Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Plays an essential role in the regulation of endothelial cell senescence and vascular aging. (UniProt, P16066)

Open in Phaseline: the race on NPR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Oslo University HospitalNesiritide
Atrial natriuretic peptide receptor A agonist
NPR1Phase 1HypertensionDec 2030

Conditions

Hypertension (1)

Modalities

protein or peptide (1)

Companies

Oslo University Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.